Literature DB >> 15194776

Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates.

Sook-Hyang Jeong1, Ming Qiao, Michelina Nascimbeni, Zongyi Hu, Barbara Rehermann, Krishna Murthy, T Jake Liang.   

Abstract

We have previously reported the production of hepatitis C virus-like particles (HCV-LP) using a recombinant baculovirus containing the cDNA of the HCV structural proteins (core, E1, and E2). These particles resemble the putative HCV virions and are capable of inducing strong and broad humoral and cellular immune responses in mice. Here we present evidence on the immunogenicity of HCV-LP and the effects of novel adjuvant systems in a nonhuman primate model, the baboon. Three groups of four baboons were immunized with HCV-LP, HCV-LP and adjuvant AS01B (monophosphoryl lipid A and QS21), or HCV-LP and the combination of AS01B and CpG oligodeoxynucleotides 10105. After four immunizations over an 8-month period, all animals developed HCV-specific humoral and cellular immune responses including antibodies to HCV structural proteins and gamma interferon(+) (IFN-gamma(+))CD4(+) and IFN-gamma(+)CD8(+) T-cell responses. The immunogenicity of HCV-LP was only marginally enhanced by the use of adjuvants. The overall HCV-specific immune responses were broad and long lasting. Our results suggest that HCV-LP is a potent immunogen to induce HCV-specific humoral and cellular immune responses in primates and may be a promising approach to develop novel preventive and therapeutic modalities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194776      PMCID: PMC421664          DOI: 10.1128/JVI.78.13.6995-7003.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Authors:  N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.

Authors:  A Takaki; M Wiese; G Maertens; E Depla; U Seifert; A Liebetrau; J L Miller; M P Manns; B Rehermann
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

3.  CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.

Authors:  E Malanchère-Brès; P J Payette; M Mancini; P Tiollais; H L Davis; M L Michel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 4.  The chimpanzee model of hepatitis C virus infections.

Authors:  R E Lanford; C Bigger; S Bassett; G Klimpel
Journal:  ILAR J       Date:  2001

5.  Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection.

Authors:  S E Bassett; B Guerra; K Brasky; E Miskovsky; M Houghton; G R Klimpel; R E Lanford
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

6.  Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

Authors:  X Paliard; Y Liu; R Wagner; H Wolf; J Baenziger; C M Walker
Journal:  AIDS Res Hum Retroviruses       Date:  2000-02-10       Impact factor: 2.205

7.  Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.

Authors:  X Forns; P J Payette; X Ma; W Satterfield; G Eder; I K Mushahwar; S Govindarajan; H L Davis; S U Emerson; R H Purcell; J Bukh
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

8.  Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection.

Authors:  K M Chang; R Thimme; J J Melpolder; D Oldach; J Pemberton; J Moorhead-Loudis; J G McHutchison; H J Alter; F V Chisari
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

9.  CpG DNA induces stronger immune responses with less toxicity than other adjuvants.

Authors:  R D Weeratna; M J McCluskie; Y Xu; H L Davis
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

10.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  42 in total

Review 1.  Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments.

Authors:  Philip Wintermeyer; Jack R Wands
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

2.  Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

Authors:  Fu-Shi Quan; Chunzi Huang; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

3.  Human immunodeficiency virus-like particles activate multiple types of immune cells.

Authors:  Gangadhara Sailaja; Ioanna Skountzou; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2007-02-05       Impact factor: 3.616

4.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.

Authors:  M Jaber Hossain; Melissa Bourgeois; Fu-Shi Quan; Aleksandr S Lipatov; Jae-Min Song; Li-Mei Chen; Richard W Compans; Ian York; Sang-Moo Kang; Ruben O Donis
Journal:  Clin Vaccine Immunol       Date:  2011-10-26

Review 6.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen.

Authors:  Sue Stacy; Amanda Pasquali; Valerie L Sexton; Angelene M Cantwell; Ellen Kraig; Peter H Dube
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 8.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.

Authors:  Baojing Lu; Yi Huang; Li Huang; Bao Li; Zhenhua Zheng; Ze Chen; Jianjun Chen; Qinxue Hu; Hanzhong Wang
Journal:  Immunology       Date:  2010-04-06       Impact factor: 7.397

10.  Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees.

Authors:  Gamal A Elmowalid; Ming Qiao; Sook-Hyang Jeong; Brian B Borg; Thomas F Baumert; Ronda K Sapp; Zongyi Hu; Krishna Murthy; T Jake Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.